Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
Status:
Recruiting
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S)
in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line
treatment of multiple myeloma (MM).
FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies,
and DRd is also already approved by the FDA for multiple myeloma. This study will use all
four (S-DRd) together to treat MM as an initial treatment.